Bigot Pierre

Professor of Urology@CHUAngers

[World Journal of Urology @wjurol]

On behalf of the Editorial Board of the World Journal of Urology, we extend our warmest wishes for a Merry Christmas and a Happy New Year. May the coming year bring health, peace, and continued scientific progress.

[Mirrors of Medicine @mirrorsmed]

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC)

https://t.co/A3aECDJyZg

In patients with BCG-naive, high-risk non-muscle-invasive #BladderCancer (NMIBC), recurrence and progression after standard transurethral resection of bladder tumor (TURBT) and BCG therapy remain significant challenges.

This phase 3, randomized, open-label trial evaluated whether adding 1 year of durvalumab to BCG therapy could improve outcomes compared with BCG alone. A total of 1,018 patients were randomized to durvalumab plus BCG induction and maintenance, durvalumab plus BCG induction only, or BCG induction and maintenance alone. At a median follow-up of approximately 5⃣ years, the combination of durvalumab with BCG induction and maintenance reduced the risk of disease recurrence or death by 32% compared with BCG alone (hazard ratio 0.68), with a manageable safety profile.

These findings suggest that durvalumab combined with BCG induction and maintenance may offer a new, effective treatment option for patients with high-risk NMIBC.

@mdesantis234
@joanfundi
@DrFelixGuerrero
@docjavip
@tompowles1
@BigotP

[Toni Choueiri, MD @DrChoueiri]

Bladder cancer #ESMO25 in 1 slide. #goosebumps #newSOCnow #micdrop #standingovation

Neoadjuvant EVP = New SOC MIBC Cis-ineligible!

[Bigot Pierre @BigotP]

@Ugobernalicis @ALeaument Champs de Martyrs à Saint Florent de Viel. 2000 femmes, enfants et hommes fusillés. Populicide commandité par Robespierre. Un exemple parmi d’autres… comment peut-on célébrer cela?!

[Gabriel Malouf @GabrielMalouf]

Excited to share results from our French national UroCCR network regarding racial disparities in RCC, with black patients showing highly likelihood for presenting rare variants of RCC. Thanks for @uroccr collaborators and team #CARARE #icans @kidneycan @kcCURE @BigotP

[Morgan Roupret @MRoupret]

Fantastic success for the @AFUrologie and #GETUG @ASCO American Society of Clinical Oncology (ASCO) society #GU25 with the release of the first data phase 2 trial about neo adjuvant systemic combo treatment of chemotherapy and immunotherapy before radical nephroureterectomy.
• 50 patients included over 3 years in 10 French centers.
• Feasibility: confirmed.
• Tolerance: no grade 3/4 adverse events related to immunotherapy.
• Response: 13% pT0 and 50% <pT1 in the cisplatin arm.

These data are displayed in a simultaneous publication of this trial in the Journal of Clinical Oncology
https://t.co/JUxa1J9WL6 @JCO_ASCO

Let's keep moving forward to the Phase III 🤓

@HouedeN

@FAudenet @Neuzillet @amassonlecomte @evanguelosx @delataillealex

@pouessel @ThierryCheval @laconss @ChristineAbraha @Glulu80

@Uroweb
@afufuro
#eauguidelines

[Bigot Pierre @BigotP]

@LigueCancer49 @chu_angers @CecileJaglin @Prefet49 @Angers Merci mille fois à la ligue 49 et ses donateurs. Cela ouvre de très nombreuses perspectives en soin et recherche clinique

[Bigot Pierre @BigotP]

@MejeanArnaud @hopital_necker @HopitalPompidou @APHP @univ_paris_cite Bravo à toute l’équipe de l’HEGP. Tu as raison Arnaud. C’est magnifique.

[AFUF @afufuro]

L'@afufuro vous présente son nouveau conseil d'administration ! 🚀

Une nouvelle mandature débute aujourd'hui autour d'un bureau élargi avec @denis_seguier Président, @GaelleMargue Vice-présidente, @ArthurPeyrottes Secrétaire et @S_Levy_Urologue Trésorier.
#CFU2024
@AFUrologie

[Bigot Pierre @BigotP]

@SigLasocki @chu_angers @SFAR_ORG @cnear_fr Je comprends mieux cette volonté d’épargner la transfusion 🩸 @chu_angers 😁

[CHU Angers @chu_angers]

💙 #NovembreBleu 💙 || Campagne de dépistage pour les hospitaliers #CancersMasculins👨‍⚕️

🗓 𝗗𝗲𝘀 𝗰𝗿𝗲́𝗻𝗲𝗮𝘂𝘅 𝘀𝗼𝗻𝘁 𝗱𝗶𝘀𝗽𝗼𝗻𝗶𝗯𝗹𝗲𝘀 𝗱𝗲̀𝘀 𝗹𝗲 𝗹𝘂𝗻𝗱𝗶 𝟰 𝗻𝗼𝘃𝗲𝗺𝗯𝗿𝗲, 𝗱𝗲 𝟵𝗵 𝗮̀ 𝟭𝟮𝗵 ❗

🖥️ Toutes les infos sur l'intranet du #CHUAngers

[MINT @LabMint]

Bravo @frlagarce de @LabMint et @chu_angers pour cette article dans @science_et_vie !!

[Bigot Pierre @BigotP]

@UrologieParis @APHP @S_Lambermont @fsimon05 @LaurentGenser @UP_Medecine @univ_paris_cite @Sorbonne_Univ_ @univ_spn @UnivParisSaclay @uvsq @UPECactus @sub_specie Bravo Marco! Une chance pour les étudiants.

[Nazareno Suardi @urosuardi]

What a surgery! Congrats to JC Bernhard and team for their impressive job. #erus24

[UroCCR @uroccr]

📢 Nouvelle Actualité!

Félicitations au Dr Mark Purdue du National Cancer Institute (NCI) pour la parution dans Nature Genetics.(UroCCR n°53)👏
▶️Retrouvez l'intégralité de l'article sur le site d'UroCCR :https://t.co/0ALzdINgFg

#kidneycancer #urology #research #genes #cancer

[Julien Sarkis @Julien__Sarkis]

Happy to see our @uroccr NEPRAH study published in European Urology Oncology @eurouroonc
@CCAFU @AFU @AlexIngels @UrologieMondor

https://t.co/BXTY9eG4WP

29 🇫🇷 French centers
3451 Patients included

[Lasocki @SigLasocki]

Bravo 🎖️@GuBouhours

[Pr. Alexandre de La Taille @delataillealex]

Congrats Olivier to take the lead of this strategic group and to be one of our French KOL around the world! @AFUrologie @afufuro

[Ligue 1 McDonald's @Ligue1]

Welcome ! 🎉

[UroCCR @uroccr]

📢 [EAU 2024]

9 présentations du réseau @uroccr lors de #EAU24.

#Félicitation pour leurs études

#EAU24 #research #urology #kidneycancer

@GaelleMargue @KhaddadAbder